The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Table 2 Univariate analysis in patients

Variables	OR (95 % Cl)	P
Sex (male vs. female)	0.880 (0.360–2.153)	0.779
Age (≤54 vs. >54)	1.003 (0.411–2.447)	0.995
TNM stage (I, II vs. III, IV)	1.310 (0.297–5.777)	0.722
Chemotherapy (no vs. yes)	0.419 (0.160–1.100)	0.077
Radiation therapy (no vs. yes)	0.643 (0.177–2.337)	0.502
Surgery (no vs. yes)	0.983 (0.398–2.430)	0.971
Molecular targeted therapy (no vs. yes)	0.671 (0.123–3.659)	0.645
Physiotherapy (no vs. yes)	0.594 (0.044–7.968)	0.694
Interventional treatment (no vs. yes)	0.615 (0.174–2.171)	0.450

ISSN: 2162-3619